
Adalimumab-adbm (Cyltezo Pen; Boehringer Ingelheim) is approved by the FDA as an interchangeable biosimilar to Humira.

Adalimumab-adbm (Cyltezo Pen; Boehringer Ingelheim) is approved by the FDA as an interchangeable biosimilar to Humira.

Death occurs from air embolism after pneumatic line was connected to an intravenous catheter.

The diagnosis should change from an influenza infection if the patient has gradually increasing chest pain after the original diagnosis.

Anne Cassity, JD, senior vice president of Public Affairs at the National Community Pharmacists Association discusses congressional and lawmaker trends on pharmacy benefits manager reform with guests, Adam Harbison and Kaite Krell.

The risk of long COVID-19 in females in the least deprived areas was comparable to the risk of males in the most deprived areas.

A barrier in effectively treating HIV has been the latency of infected CD4+ T cells, which are often treatment-resistant and contribute to the persistence nature of the virus.

Long-term data show that early treatment with ofatumumab decreased confirmed disability worsening in nearly all study patients with relapsing multiple sclerosis.

Products include a 3-in-1 probiotic product and OTC hearing aids.

OTC nicotine replacement products can come in a transdermal patch, nicotine gum, or lozenges.

The approval marks the first and only FDA-approved treatment for dry eye disease that directly targets tear evaporation.

These appointments help identify medication-related problems and serve as a platform for additional education.

Nanoparticles could improve the solubility of drugs, aid in treatment escape from the immune system, and increase the half-life of drugs in the circulatory system against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus.

Targeted PrEP advertisements with different types of couples and sociodemographic characteristics were more eye-catching, motivating, relatable, and memorable.

Amid various obstacles, health care providers and pharmacists can initiate measures to enhance compensation for pharmacy services in managed care.

In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.

Study finds that a more accurate estimate of the burden of RSV disease will facilitate appropriate decision making regarding the use of preventive interventions, such as vaccination.

As demand increases, pharmacies can diversify by offering brain-function assessments to patients.

Improving awareness and getting involved in local or national initiatives can enable pharmacists to make change.

Christina Madison sat down with Walter Oronsaye, known as the Phit Pharmacist, to discuss over prescribing as well as social media as a tool for pharmacists.

At least 150 minutes per week of moderate intensity aerobic activity, or 75 minutes of vigorous intensity aerobic activity found to improve outcomes in patients with flu or pneumonia.

Federal legislation addresses variety of issues and seeks to build on gains made under the Affordable Care Act.

Experts have seen the value of technology in the clinical trial space because it helps to remove natural bias that can leads to inaccuracies in data collection.

Good practice for older adults is that calories should go down while nutrient intake goes up as they age.

Common chronic pain conditions included in the analysis were fibromyalgia, neuropathic pain, and musculoskeletal pain.

Health care professionals should educate patients that it is possible to effectively manage pain without opioids.

Skinvive by Juvéderm is a first of its kind medication to create skin smoothness that lasts 6 months with optimal treatment.

Teva is unable to meet demand for dextroamphetamine/amphetamine, and other companies struggle to keep up.

Patients who did not have health care coverage were found to have a significantly higher mean HbA1c levels among adults with diabetes.

Study evaluates the effect of long-acting monoclonal antibodies tixagevimab and cilgavimab treating COVID-19 symptoms and viral shedding.

Hospitalization costs from respiratory syncytial virus infection are driven by older age and comorbidities.